FI3981414T3 - Suuren pinta-alan kylmäkuivattuja, arseenia käsittäviä, potilaille suun kautta annettavia koostumuksia - Google Patents
Suuren pinta-alan kylmäkuivattuja, arseenia käsittäviä, potilaille suun kautta annettavia koostumuksiaInfo
- Publication number
- FI3981414T3 FI3981414T3 FIEP21192594.6T FI21192594T FI3981414T3 FI 3981414 T3 FI3981414 T3 FI 3981414T3 FI 21192594 T FI21192594 T FI 21192594T FI 3981414 T3 FI3981414 T3 FI 3981414T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- as2o3
- leukemia
- myeloma
- lyophilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110574P | 2015-02-01 | 2015-02-01 | |
| US201562142709P | 2015-04-03 | 2015-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3981414T3 true FI3981414T3 (fi) | 2025-07-29 |
Family
ID=56544541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21192594.6T FI3981414T3 (fi) | 2015-02-01 | 2016-02-01 | Suuren pinta-alan kylmäkuivattuja, arseenia käsittäviä, potilaille suun kautta annettavia koostumuksia |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10111836B2 (enExample) |
| EP (3) | EP3250214B1 (enExample) |
| JP (3) | JP6928768B2 (enExample) |
| CN (2) | CN117899029A (enExample) |
| AU (4) | AU2016211186A1 (enExample) |
| CA (2) | CA2975406C (enExample) |
| DK (1) | DK3981414T3 (enExample) |
| ES (2) | ES2899226T3 (enExample) |
| FI (1) | FI3981414T3 (enExample) |
| HR (1) | HRP20251032T1 (enExample) |
| HU (1) | HUE072537T2 (enExample) |
| LT (1) | LT3981414T (enExample) |
| MX (2) | MX390835B (enExample) |
| PL (1) | PL3981414T3 (enExample) |
| PT (1) | PT3981414T (enExample) |
| RS (1) | RS67133B1 (enExample) |
| SI (1) | SI3981414T1 (enExample) |
| SM (1) | SMT202500321T1 (enExample) |
| TW (3) | TWI790191B (enExample) |
| WO (1) | WO2016123603A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI790191B (zh) | 2015-02-01 | 2023-01-21 | 美商錫羅斯製藥公司 | 用於病患口服之含砷高表面積冷凍乾燥組合物 |
| PL3548044T3 (pl) | 2016-12-01 | 2024-03-04 | Eupharma Pty Ltd | Kompozycje arsenu |
| KR101844049B1 (ko) | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
| KR101844050B1 (ko) | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| WO2018134260A1 (en) * | 2017-01-18 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
| US11583552B2 (en) | 2021-02-17 | 2023-02-21 | Manoj Maniar | Pharmaceutical formulation of arsenic trioxide |
| JP7428842B1 (ja) | 2023-03-29 | 2024-02-06 | ａｒｔｉｅｎｃｅ株式会社 | 活性エネルギー線硬化型インキ、その製造方法、および印刷物 |
| WO2025172482A1 (en) | 2024-02-14 | 2025-08-21 | Institut Gustave Roussy | Oral composition of arsenic trioxide for cancer treatment |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773419A (en) | 1995-03-03 | 1998-06-30 | Falcon; Juan | Method of treating cancer with tannic acid |
| CN1044559C (zh) | 1995-08-23 | 1999-08-11 | 哈尔滨医科大学附属第一医院 | 抗白血病、肝癌、淋巴瘤注射液 |
| EP1964557B1 (en) | 1997-11-10 | 2013-01-02 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations |
| US7276359B1 (en) * | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| CN1131922C (zh) | 1998-10-19 | 2003-12-24 | 张在喆 | 一种通过弹性键搭架与收拢的帐篷 |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| CN102772413A (zh) * | 2000-02-29 | 2012-11-14 | 布里斯托尔-迈尔斯斯奎布公司 | 低剂量艾替开韦制剂及其应用 |
| AUPR874601A0 (en) * | 2001-11-08 | 2001-11-29 | Unisearch Limited | Selective targeting of apoptotic cells |
| US7521071B2 (en) | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| US8906422B2 (en) | 2002-10-09 | 2014-12-09 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| GB0315632D0 (en) * | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
| CN1251688C (zh) | 2003-12-09 | 2006-04-19 | 重庆维特瑞医药开发有限公司 | 三氧化二砷冻干粉针及其生产方法 |
| JP4292985B2 (ja) | 2003-12-25 | 2009-07-08 | Ｊｓｒ株式会社 | 感放射線性組成物、マイクロレンズとその形成方法および液晶表示素子 |
| CN1698650A (zh) | 2004-05-21 | 2005-11-23 | 哈尔滨伊达药业有限公司 | 一种治疗原发性肝癌的亚砷酸注射液及其制备方法 |
| CN1326528C (zh) | 2004-07-13 | 2007-07-18 | 东南大学 | 砒霜磁性纳米明胶微球的制备工艺 |
| CA2626016A1 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US20080089951A1 (en) * | 2006-10-11 | 2008-04-17 | The University Of Hong Kong | Method for Inhibiting Cancer Using Arsenic Trioxide |
| CN101322719B (zh) * | 2007-06-15 | 2012-03-07 | 杭州民生药业有限公司 | 一种三氧化二砷固体脂质纳米粒及其制剂 |
| US8168224B2 (en) * | 2007-12-19 | 2012-05-01 | Beijing Shengyiyao Science & Technology Development Co., Ltd. | Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof |
| PT2345426E (pt) | 2008-09-19 | 2014-06-09 | Activus Pharma Co Ltd | Composto orgânico compósito em pó para utilização médica, método de produção do mesmo e suspensão do mesmo |
| EP2359812A1 (en) * | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| EP2525783A1 (en) | 2010-01-18 | 2012-11-28 | Cephalon France | Improved oral lysophilisates containing pvp/va |
| CN103142648B (zh) * | 2011-12-07 | 2015-04-15 | 浙江中医药大学 | 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂 |
| CN103408477B (zh) | 2013-08-22 | 2015-06-10 | 陈鹏飞 | 一种含砷配位化合物及其制备方法 |
| MX382596B (es) | 2015-01-29 | 2025-03-13 | Eupharma Pty Ltd | Composiciones que contienen arsénico y su uso en métodos de tratamiento. |
| TWI790191B (zh) | 2015-02-01 | 2023-01-21 | 美商錫羅斯製藥公司 | 用於病患口服之含砷高表面積冷凍乾燥組合物 |
-
2016
- 2016-02-01 TW TW105103175A patent/TWI790191B/zh active
- 2016-02-01 MX MX2017009913A patent/MX390835B/es unknown
- 2016-02-01 PT PT211925946T patent/PT3981414T/pt unknown
- 2016-02-01 HR HRP20251032TT patent/HRP20251032T1/hr unknown
- 2016-02-01 CN CN202311663020.2A patent/CN117899029A/zh active Pending
- 2016-02-01 SM SM20250321T patent/SMT202500321T1/it unknown
- 2016-02-01 EP EP16744263.1A patent/EP3250214B1/en active Active
- 2016-02-01 CA CA2975406A patent/CA2975406C/en active Active
- 2016-02-01 CA CA3225480A patent/CA3225480A1/en active Pending
- 2016-02-01 TW TW111149127A patent/TW202337477A/zh unknown
- 2016-02-01 US US15/012,355 patent/US10111836B2/en active Active
- 2016-02-01 RS RS20250815A patent/RS67133B1/sr unknown
- 2016-02-01 JP JP2017559275A patent/JP6928768B2/ja active Active
- 2016-02-01 CN CN201680020478.8A patent/CN107530373B/zh active Active
- 2016-02-01 HU HUE21192594A patent/HUE072537T2/hu unknown
- 2016-02-01 EP EP25184422.1A patent/EP4599823A1/en active Pending
- 2016-02-01 LT LTEP21192594.6T patent/LT3981414T/lt unknown
- 2016-02-01 TW TW110142380A patent/TW202228734A/zh unknown
- 2016-02-01 FI FIEP21192594.6T patent/FI3981414T3/fi active
- 2016-02-01 ES ES16744263T patent/ES2899226T3/es active Active
- 2016-02-01 AU AU2016211186A patent/AU2016211186A1/en not_active Abandoned
- 2016-02-01 WO PCT/US2016/015917 patent/WO2016123603A2/en not_active Ceased
- 2016-02-01 PL PL21192594.6T patent/PL3981414T3/pl unknown
- 2016-02-01 DK DK21192594.6T patent/DK3981414T3/da active
- 2016-02-01 EP EP21192594.6A patent/EP3981414B1/en active Active
- 2016-02-01 ES ES21192594T patent/ES3034734T3/es active Active
- 2016-02-01 SI SI201631917T patent/SI3981414T1/sl unknown
-
2017
- 2017-07-31 MX MX2020012611A patent/MX2020012611A/es unknown
-
2018
- 2018-10-01 US US16/148,193 patent/US10272045B2/en active Active
-
2019
- 2019-03-12 US US16/299,214 patent/US10653628B2/en active Active
-
2020
- 2020-04-20 US US16/852,758 patent/US20210069115A1/en not_active Abandoned
-
2021
- 2021-06-07 AU AU2021203752A patent/AU2021203752B2/en active Active
- 2021-06-22 JP JP2021103196A patent/JP7539855B2/ja active Active
-
2023
- 2023-01-27 US US18/160,445 patent/US12364664B2/en active Active
- 2023-08-10 AU AU2023214307A patent/AU2023214307B2/en active Active
-
2024
- 2024-01-10 US US18/408,664 patent/US20240269076A1/en active Pending
- 2024-08-14 JP JP2024135193A patent/JP2024161468A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259861A patent/AU2025259861A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3981414T3 (fi) | Suuren pinta-alan kylmäkuivattuja, arseenia käsittäviä, potilaille suun kautta annettavia koostumuksia | |
| ES2690175T3 (es) | Nanopartícula que comprende rapamicina y albúmina como agente antineoplásico | |
| JP5645667B2 (ja) | 増殖性疾患を治療するための、Ｎ−（５−ｔｅｒｔ−ブチル−イソキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，ｌ−ｂ］［ｌ，３］ベンゾチアゾール−２−イル］フェニル｝尿素の投与方法 | |
| ES2807528T3 (es) | Complejos macrocíclicos pentaaza que poseen biodisponibilidad oral | |
| JP2018503696A5 (enExample) | ||
| US20150342872A1 (en) | Use of Paclitaxel Particles | |
| WO2010045292A2 (en) | Nanoparticle compositions comprising liquid oil cores | |
| CN101730526A (zh) | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 | |
| CN101439030A (zh) | 一种含番茄红素的药物组合物及其制备方法 | |
| AU2015326489A1 (en) | Low dose oral pharmaceutical composition of isotretinoin | |
| US9750711B2 (en) | Low dose oral pharmaceutical composition of isotretinoin | |
| JP2017516792A (ja) | 経口イソトレチノイン医薬組成物 | |
| AU2019215127A1 (en) | Pharmaceutical formulations | |
| AU2013204187B2 (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| Kasashima et al. | Oral sustained release of a hydrophilic drug using the lauryl sulfate salt/complex | |
| CN101632659A (zh) | 抗病毒药物和匹多莫德的药物组合物及其制备方法和药物应用 | |
| JP7640453B2 (ja) | 医薬製剤およびその製造方法 | |
| AU2015271950B2 (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| HK40007412A (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| CN102258526A (zh) | 一种抗肿瘤药物组合物 | |
| HK1173975B (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| HK1173975A (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| HK1248113B (zh) | 用於在患者中口服施用的含有砷的高表面积冻干组合物 | |
| HK1173977B (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent |